Xeris Biopharma Holdings, Inc. has recently completed a significant financial restructuring on March 6, 2024. The company successfully refinanced its $150 million senior secured term loan facility with Hayfin Capital Management LLP.
This restructuring involved drawing down $200 million to repay the existing term loan, resulting in improved financial stability and reduced costs for Xeris. The move signifies a strategic decision to enhance the company’s financial position and gain access to substantial capital.
By partnering with Hayfin Capital Management LLP, Xeris aims to improve its cost of capital and strengthen its overall financial standing. This refinancing marks a crucial step for Xeris in achieving long-term financial success and stability.
Xeris Pharmaceuticals, Inc. (XERS) Stock Performance Review: March 6, 2024
Xeris Pharmaceuticals, Inc. (XERS) had a mixed day in the stock market on March 6, 2024. The pharmaceutical company’s stock performance was closely watched by investors as it traded in the middle of its 52-week range and above its 200-day simple moving average.
The day started off on a positive note for XERS as the price of its shares increased by $0.04 since the market last closed. This represented a 1.32% rise, with the stock closing at $3.08. However, things took a turn in pre-market trading as the stock dropped by $0.06.
Despite the drop in pre-market trading, XERS still showed signs of resilience as it remained above its 200-day simple moving average. This moving average is often used by investors to gauge the overall trend of a stock’s price movement over a longer period of time.
Xeris Pharmaceuticals has been making strides in the pharmaceutical industry with its innovative products and solutions. The company is known for its focus on developing ready-to-use, room-temperature stable injectable glucagon for the treatment of severe hypoglycemia.
XERS Stock Shows Strong Performance with Impressive Financial Results on March 6, 2024
XERS stock had a strong performance on March 6, 2024, as the company reported impressive financial results. According to data from CNN Money, XERS total revenue stood at $110.25 million for the past year, representing a significant increase of 122.32% compared to the previous year. In the most recent quarter, the company generated $48.32 million in revenue, marking a 27.13% increase from the previous quarter.
The net income for XERS was reported as -$94.66 million for the past year, but this figure improved by 22.87% to -$12.19 million in the most recent quarter. This shows a positive trend in the company’s financial performance, with a notable increase of 38.57% in net income since the previous quarter.
Earnings per share (EPS) for XERS also saw a significant improvement, with a reported figure of -$0.70 for the past year. However, this metric increased by 55.06% to -$0.09 in the most recent quarter, indicating a strong growth trajectory for the company. The 38.89% increase in EPS since the previous quarter further highlights XERS’ positive momentum.
Overall, XERS stock demonstrated strong performance on March 6, 2024, with impressive growth in total revenue, net income, and earnings per share. Investors may view these financial results as a positive indicator of the company’s financial health and growth potential.
